COSMEGEN LYOVAC POWDER FOR SOLUTION FOR INJECTION

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

DACTINOMYCIN

Available from:

Lundbeck Pharmaceuticals Ireland

Dosage:

0.5 Milligram

Pharmaceutical form:

Pdr for Soln for Injection

Authorization date:

2006-09-01

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cosmegen
®
Lyovac* 500 micrograms Powder for Solution for Injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial provides 500 micrograms Dactinomycin.
When reconstituted as directed, the resulting solution will contain 500 micrograms Dactinomycin per mL.
For a full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Powder for solution for injection.
A yellow/orange lyophilised powder.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
‘Cosmegen’ is a cytotoxic, antineoplastic antibiotic with immunosuppressant properties.
‘Cosmegen’, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the
treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, and metastatic nonseminomatous
testicular cancer.
‘Cosmegen’ is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of
gestational trophoblastic neoplasia.
‘Cosmegen’, as a component of regional perfusion in combination with melphalan, is indicated for the treatment of
locally recurrent or locoregionally metastatic melanoma.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Toxic reactions due to ‘Cosmegen’ are frequent and may be severe (see 4.8 ‘Undesirable effects’), thus limiting the
amount that may be given in many cases. However, the severity of toxicity varies markedly and is only partly
dependent on the dosage used.
The dosage of ‘Cosmegen’ will vary with the tolerance of the patient, the size and location of the neoplasm, and the use
of other forms of therapy. It may be necessary to reduce the usual dosage suggested below when additional
chemotherapy or radiation therapy is used concurrently, or has been employed previously.
The dosag
                                
                                Read the complete document
                                
                            

Search alerts related to this product